Premium
Effect of peroxisome proliferator‐activated receptor‐ α agonist (bezafibrate) on gastric secretion and gastric cytoprotection in rats
Author(s) -
Pathak Rahul,
Asad Mohammed,
Jagannath Hrishikeshavan H.,
Prasad Satya
Publication year - 2007
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2007.00475.x
Subject(s) - bezafibrate , cytoprotection , agonist , medicine , gastric acid , endocrinology , peroxisome proliferator activated receptor , pharmacology , acetic acid , stomach , receptor , chemistry , biochemistry , oxidative stress
The effect of peroxisome proliferator‐activated receptor‐ α (PPAR‐ α ) on gastric secretion and gastric cytoprotection was evaluated using five different models of gastric ulcers: acetic acid‐induced chronic gastric ulcers, pylorus ligation, ethanol‐induced, indomethacin‐induced and ischemia–reperfusion‐induced gastric ulcers. Bezafibrate, a PPAR‐ α agonist was administered at two different doses of 10 and 100 mg/kg body weight intraperitoneanally. Both doses of bezafibrate showed significant antiulcer effect in ethanol‐induced, indomethacin‐induced and pylorus ligation‐induced gastric ulcers. Bezafibrate increased healing of ulcer in acetic acid‐induced chronic gastric ulcer model. Both doses were also effective in preventing gastric lesions induced by ischemia–reperfusion. It was concluded that PPAR‐ α activation increases healing of gastric ulcers and also prevents development of gastric ulcers in rats.